Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Deciphera Pharmaceuticals, Inc.

Akebia Therapeutics is a fully integrated biopharmaceutical company that addresses complications of kidney disease, with two FDA-approved products.

Akebia Therapeutics

Deciphera is focused on developing kinase inhibitors to improve patient outcomes in cancer treatment.

Metric
Company Name	Deciphera Pharmaceuticals, Inc.	Akebia Therapeutics
Symbol	DCPH
MSH ID	COM:DECIPHERA	COM:KERYX
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Biotechnology
Country	US	US
Stage
Employee Count	355
Website	deciphera.com	keryx.com
LinkedIn
Founders

Metric
Market Cap	2.21B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	163.36M
Revenue (LTM)
Revenue (NTM)
Gross Profit	159.62M
EBITDA	-210.96M
Operating Income	-210.96M
Net Income	-194.94M
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.98
Operating Profit Margin	-1.18
EBITDA Margin	-1.29
Net Profit Margin	-1.09
Return on Equity	-0.49
Return on Assets	-0.41
Return on Capital Employed	-0.57

COM:DECIPHERA

Deciphera

Last Close

25.57

10/06 20:00

Market Cap

2.21B

Beta: -

Volume Today

1.57M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.58
P/B Ratio	3.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	12.79
EV Multiple	-6.24

Metric
Days Sales Outstanding	66.41
Days Payables Outstanding	1.51K
Days Inventory Outstanding	2.07K
Operating Cycle	2.15K
Cash Conversion Cycle	154.54
Asset Turnover	0.42

Metric
Operating Cash Flow	-146.70M
Free Cash Flow	-147.47M
Cash Flow to Debt	-5.67
Operating Cash Flow/Sales	-0.87
Free Cash Flow Yield	-0.13

Metric
Cash & Equivalents	83.51M
Accounts Receivable	-9.35M
Inventory	21.21M
Goodwill
Debt to Capitalization	0.07
Debt to Assets	0.05
Current Ratio	4.50
Quick Ratio	3.66

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.32
R&D to Revenue	1.48
SG&A to Revenue